Is HAE a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Plasma without the CSL overhang, with revenue (ttm) at ~$1.35B. The bear case rests on customer concentration is the structural risk: plasma collection in the United States is consolidated into a handful of buyers, and the CSL departure showed how much revenue a single non-renewal can remove. Analysts covering it are spread from $86.00 to $105.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Customer concentration is the structural risk: plasma collection in the United States is consolidated into a handful of buyers, and the CSL departure showed how much revenue a single non-renewal can remove. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $86.00, -5.3% from the $90.80 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Plasma without the CSL overhang. For the first time in several years, plasma revenue is being compared against a base that no longer contains the departed CSL volumes. The most optimistic analyst target on HAE is $105.00, +15.6% from the $90.80 price. That figure is only reachable if this thesis works close to its best case.

Customer concentration is the structural risk: plasma collection in the United States is consolidated into a handful of buyers, and the CSL departure showed how much revenue a single non-renewal can remove. Immunoglobulin demand has been reliable but is not guaranteed, and any move by a large customer toward in-house or competing collection hardware would repeat the problem. The interventional portfolio was assembled through three acquisitions in roughly two years, which leaves goodwill and intangibles on the balance sheet and convertible debt against them, and the pulsed field ablation transition has already demonstrated that a procedure-mix shift can cut into those products faster than the thesis assumed. The blood center business continues to decline as hospitals use less transfused blood, so mix has to keep improving just to hold consolidated growth flat. Tariffs, medical-device quality regulation and the pace of hospital capital budgets are the usual additional constraints on a company that manufactures physical disposables at scale. The most pessimistic published target is $86.00, -5.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Plasma collection systems and disposables, plus hospital products including VASCADE vascular closure and TEG diagnostics.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Plasma without the CSL overhang) stalling in the reported numbers rather than in the narrative, the risk above (customer concentration is the structural risk: plasma collection in the United States is consolidated into a handful of buyers, and the CSL departure showed how much revenue a single non-renewal can remove) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Machines and, more importantly, the single-use disposable kits that run on them. Plasma collection devices sit in donation centers, and hospital products include vascular closure devices, hemostasis analyzers and autotransfusion systems. The recurring disposable revenue, not the hardware, is where most of the margin comes from.

CSL Plasma was Haemonetics' largest plasma customer. It chose not to renew its supply agreement and moved to a competing collection device, with transitional supply running off through fiscal 2025. The revenue removed was in the roughly $70 million to $100 million range, which suppressed reported growth for two fiscal years. Fiscal 2027 is the first year comparing against a base without it.

In the quarter ended June 2026, plasma revenue grew about 8% organically, and total company revenue reached about $339 million, up roughly 6%. That is the first clean quarter without CSL distorting the comparison. Whether mid to high single digits persists depends on immunoglobulin demand and on the Persona PLUS yield rollout at existing customers.